A5070009221- Autoimmune and Inflammatory Disorders Research
- Systemic Sclerosis and Related Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Inflammasome and immune disorders
- Inflammatory Myopathies and Dermatomyositis
- Adolescent and Pediatric Healthcare
- Systemic Lupus Erythematosus Research
- Kawasaki Disease and Coronary Complications
- Dermatologic Treatments and Research
- Rheumatoid Arthritis Research and Therapies
- Ocular Diseases and Behçet’s Syndrome
- Dermatological and Skeletal Disorders
- Eosinophilic Disorders and Syndromes
- Autoimmune Bullous Skin Diseases
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Vasculitis and related conditions
- Otitis Media and Relapsing Polychondritis
- Renal Diseases and Glomerulopathies
- Skin Diseases and Diabetes
- Orthopedic Infections and Treatments
- Mast cells and histamine
- Connective tissue disorders research
- Neurogenetic and Muscular Disorders Research
- Diabetes and associated disorders
University of Padua
2016-2025
Azienda Ospedaliera di Padova
2024
Istituti di Ricovero e Cura a Carattere Scientifico
1998-2018
Istituto Giannina Gaslini
2008-2018
Cincinnati Children's Hospital Medical Center
2018
Sydney Children's Hospital
2018
University of Cincinnati
2018
Bambino Gesù Children's Hospital
2018
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2018
Ospedale Maggiore
2018
Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA; treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA.We randomly assigned 112 children, 2 to 17 years age, with active JIA (duration ≥6 months and inadequate responses nonsteroidal antiinflammatory drugs glucocorticoids) anti-interleukin-6 receptor antibody tocilizumab (at dose 8 mg per kilogram body weight if was ≥30 kg or 12 <30 kg) placebo given intravenously every weeks during...
Purpose: The optimal treatment of systemic sclerosis (SSc) is a challenge because the pathogenesis SSc unclear and it an uncommon clinically heterogeneous disease affecting multiple organ systems. aim European League Against Rheumatism (EULAR) Scleroderma Trials Research group (EUSTAR) was to develop evidence-based, consensus-derived recommendations for SSc. Methods: To obtain maintain high level intrinsic quality comparability this approach, EULAR standard operating procedures were...
Objective. Juvenile localized scleroderma (JLS) includes a number of conditions often grouped together. With the long-term goal developing uniform classification criteria, we studied epidemiological, clinical and immunological features children with JLS followed by paediatric rheumatology dermatology centres.
Abstract Objective To evaluate the safety and efficacy of infliximab in treatment juvenile rheumatoid arthritis (JRA). Methods This was an international, multicenter, randomized, placebo‐controlled, double‐blind study. One hundred twenty‐two children with persistent polyarticular JRA despite prior methotrexate (MTX) therapy were randomized to receive or placebo for 14 weeks, after which all received through week 44. Patients MTX plus 3 mg/kg 44, weeks followed by 6 Results Although a higher...
Abstract Objective To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate dosage (15 mg/m 2 /week) versus a higher (30 in patients with polyarticular‐course juvenile idiopathic arthritis (JIA) who failed to improve while receiving standard dosages MTX (8–12.5 /week). Methods In screening phase, 595 were newly started on dose followed up for 6 months. Subsequently, nonresponders, defined according American College Rheumatology (ACR) pediatric 30% improvement...
Juvenile localized scleroderma is usually considered a disease that confined to the skin and subcutaneous tissue. We studied prevalence clinical features of extracutaneous manifestations in large cohort children with juvenile scleroderma.Data from multinational study on was used for this in-depth study. Clinical patients were compared those who had exclusively involvement.Seven hundred fifty entered One sixty-eight (22.4%) presented total 193 manifestations, as follows: articular (47.2%),...
Abstract Objective To investigate the long‐term outcome and prognostic factors of juvenile dermatomyositis (DM) through a multinational, multicenter study. Methods Patients consisted inception cohorts seen between 1980 2004 in 27 centers Europe Latin America. Predictor variables were sex, continent, ethnicity, onset year, age, type, manifestations, course disease duration, active duration. Outcomes muscle strength/endurance, continued activity, cumulative damage, cutaneous calcinosis,...
To report methodology and overall clinical, laboratory radiographic characteristics for Henoch-Schönlein purpura (HSP), childhood polyarteritis nodosa (c-PAN), c-Wegener granulomatosis (c-WG) c-Takayasu arteritis (c-TA) classification criteria.The preliminary Vienna 2005 consensus conference, which proposed criteria paediatric vasculitides, was followed by a EULAR/PRINTO/PRES - supported validation project divided into three main steps. Step 1: retrospective/prospective web-data collection...
To determine the clinical and immunologic features of systemic sclerosis (SSc) in a large group children describe evolution disease compare it with adult form.Data on 153 patients juvenile SSc collected from 55 pediatric rheumatology centers Europe, Asia, South North America were analyzed. Demographic, clinical, characteristics at onset, diagnosis, during course evaluated.Raynaud's phenomenon was most frequent symptom, followed by skin induration approximately 75% patients. Musculoskeletal...
Objective Osteopenia/osteoporosis is being increasingly reported as a complication of many chronic diseases, even in children. In this preliminary study, we evaluated the effect an oral bisphosphonate (alendronate) on bone mass children with diffuse connective tissue diseases. Methods Thirty-eight low were treated alendronate for 1 year; 38 who had same primary disorders study patients but less severe form served untreated control patients. We also able to evaluate changes (before and after...
Juvenile localized scleroderma is a chronic progressive fibrotic disorder of the skin that causes permanent disability and aesthetic damage. This study was undertaken to assess safety efficacy methotrexate (MTX) in treatment juvenile scleroderma.In this double-blind study, patients with active were randomized (2:1) receive oral MTX (15 mg/m², maximum 20 mg) or placebo once weekly, for 12 months until failure. Both groups received prednisone (1 mg/kg/day, 50 first 3 months. A target lesion...
Abstract Objective To develop criteria for the classification of systemic sclerosis (SSc) in children (juvenile SSc). Methods The study consisted 3 phases: 1) collection data on signs and symptoms actual patients with juvenile SSc that are useful defining involvement a particular organ; 2) selection parameters essential preparation set provisional (PCC) using 2 Delphi surveys; 3) consensus conference consisting steps: discussion rating clinical profiles 160 definite SSc, possible or other...
Abstract Objective To identify a set of clinical parameters that can predict the probability carrying mutations in one genes associated with hereditary autoinflammatory syndromes. Methods A total 228 consecutive patients history periodic fever were screened for MVK , TNFRSF1A and MEFV genes, detailed information was collected. diagnostic score formulated based on univariate multivariate analyses genetically positive negative (training set). The validated an independent 77 (validation Results...
Objective. Pharmacokinetic studies have shown that the biological effect of triamcinolone acetonide (TA) is equivalent to hexacetonide (TH), if used at double dosage. In this study we compared efficacy intra-articular TA a dose twice TH in symmetrically involved joints, children with juvenile idiopathic arthritis (JIA).
To evaluate the safety and efficacy of abatacept in patients with severe juvenile idiopathic arthritis (JIA)-related uveitis refractory or intolerant to immunosuppressive anti-tumor necrosis factor alpha (anti-TNFalpha) agents.Patients JIA-related anti-TNFalpha agents were treated intravenous (10 mg/kg monthly). Side effects, frequency flares, ocular complications before after treatment reported.Seven (6 females 1 male) a mean duration 11.6 years entered study. All had failed previous...
To analyze whether there were clinical differences between genetically positive and negative patients fulfilling periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome criteria to test the accuracy of Gaslini diagnostic score for identifying with PFAPA higher probabilities carrying relevant mutations in genes associated fevers.Complete genetic information was available 393 children fever; 82 had results, 75 incomplete 236 results MVK, TNFRSF1A, MEFV mutations....
Objective. To evaluate the efficacy of mycophenolate mofetil (MMF) in treatment severe refractory juvenile localized scleroderma (JLS). Methods. A retrospective chart review was performed patients with JLS who had been treated MMF after failure a combination MTX and corticosteroids for at least 4 months, or whose concomitant extracutaneous manifestations. Outcome assessed through clinical examination thermography. Adverse events were recorded. Results. Ten (six females four males) enrolled...
Objective. To evaluate safety and efficacy of adalimumab (ADA) infliximab (IFX) for the treatment juvenile idiopathic arthritis-related anterior uveitis (JIA-AU). Methods. Starting January 2007, patients with JIA-AU treated IFX ADA were managed by a standard protocol data entered into National Italian Registry (NIR). At baseline, all refractory to immunosuppressive and/or corticosteroid-dependent. Data recorded every 3 months included course, number/type ocular complications, drug-related...